SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Germany · Delayed Price · Currency is EUR 23.05
-0.25 (-1.07%)
At close: Sep 4, 2026
ETR:1SXP Ratios and Metrics
Market cap in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 3,472 | 3,178 | 4,618 | 4,765 | - | - | |
Market Cap Growth | 5.49% | -31.18% | -3.10% | - | - | - |
Enterprise Value | 3,757 | 3,440 | 4,867 | 4,914 | - | - |
Last Close Price | 23.05 | 20.84 | 30.07 | 30.91 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
PE Ratio | 25.62 | 21.70 | 30.85 | 31.38 | - | - |
Forward PE | 19.38 | 19.36 | 30.23 | - | - | - |
PS Ratio | 3.41 | 3.22 | 4.83 | 5.30 | - | - |
PB Ratio | 3.48 | 3.56 | 5.86 | 6.89 | - | - |
P/TBV Ratio | 3.60 | 3.69 | 6.11 | 7.23 | - | - |
P/FCF Ratio | 62.92 | 89.28 | 57.95 | 770.48 | - | - |
P/OCF Ratio | 18.00 | 17.66 | 20.55 | 26.23 | - | - |
PEG Ratio | 2.53 | 1.71 | 2.66 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
EV/Sales Ratio | 3.70 | 3.49 | 5.09 | 5.47 | - | - |
EV/EBITDA Ratio | 13.86 | 13.25 | 19.55 | 22.59 | - | - |
EV/EBIT Ratio | 20.49 | 18.52 | 25.77 | 28.70 | - | - |
EV/FCF Ratio | 68.09 | 96.63 | 61.07 | 794.52 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Debt / Equity Ratio | 0.31 | 0.34 | 0.36 | 0.30 | 0.28 | 0.24 |
Debt / EBITDA Ratio | 1.21 | 1.14 | 1.13 | 0.94 | 0.92 | 0.67 |
Debt / FCF Ratio | 5.59 | 8.51 | 3.59 | 33.92 | 6.49 | 2.95 |
Net Debt / Equity Ratio | 0.28 | 0.31 | 0.33 | 0.27 | 0.23 | 0.17 |
Net Debt / EBITDA Ratio | 1.14 | 1.07 | 1.04 | 0.85 | 0.78 | 0.48 |
Net Debt / FCF Ratio | 5.14 | 7.79 | 3.26 | 29.74 | 5.48 | 2.13 |
Asset Turnover | 0.63 | 0.65 | 0.72 | 0.74 | 0.85 | 0.97 |
Inventory Turnover | 4.13 | 4.07 | 4.45 | 4.35 | 4.94 | 5.76 |
Quick Ratio | 0.74 | 0.75 | 0.66 | 0.80 | 0.80 | 0.80 |
Current Ratio | 1.61 | 1.50 | 1.34 | 1.33 | 1.72 | 1.24 |
Return on Equity (ROE) | 14.67% | 17.47% | 20.31% | 21.69% | 22.30% | 27.53% |
Return on Assets (ROA) | 6.49% | 7.65% | 8.84% | 8.81% | 10.85% | 10.71% |
Return on Invested Capital (ROIC) | 10.46% | 13.10% | 16.04% | 16.00% | 19.55% | 21.34% |
Return on Capital Employed (ROCE) | 13.40% | 16.20% | 18.80% | 19.40% | 19.20% | 23.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Earnings Yield | 3.92% | 4.61% | 3.24% | 3.19% | - | - |
FCF Yield | 1.59% | 1.12% | 1.73% | 0.13% | - | - |
Dividend Yield | 0.77% | 0.86% | 0.53% | 0.48% | - | - |
Payout Ratio | 19.90% | 16.45% | 15.09% | 12.43% | 9.14% | 39.53% |
Buyback Yield / Dilution | 0.12% | - | - | - | 0.00% | - |
Total Shareholder Return | 0.89% | 0.86% | 0.53% | 0.48% | - | - |